Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled maxipost (BMS-204352) in humans

Drug Metabolism and Disposition

Volumn 33, Issue 1, 2005, Pages 83-93

  Zhang, Donglu ^a   Krishna, Rajesh ^a   Wang, Lifei ^a   Zeng, Jianing ^a   Mitroka, James ^a   Dai, Renke ^a   Narasimhan, Narayanan ^a   Reeves, Richard A ^a   Srinivas, Nuggehally R ^a   Klunk, Lewis J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; CARBON 14;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DOG; FECES; HUMAN; HUMAN CELL; ISOTOPE LABELING; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY;

ADULT; ANIMALS; BLOOD PROTEINS; CARBON RADIOISOTOPES; DOGS; HUMANS; INDOLES; MALE; PROTEIN BINDING; RATS;

ANIMALIA; CANIS FAMILIARIS;

EID: 19944412145     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001412     Document Type: Article

References (31)

1. Braun KP, Cody RB, Jones DR, and Peterson CM (1995) A structural assignment for a stable acetaldehyde-lysine adduct. J Biol Chem 270:11263-11266.
2. Chang CP, Dworetzky SI, Wang J, and Goldstein ME (1997) Differential expression of the a and b subunits of large-conductance calcium-activated potassium channel: implication for channel diversity. Mol Brain Res 45:33-40.
3. Cheney JA, Weisser JD, Bareyre FM, Laurer HL, Saatman KE, Raghupathi R, Gribkoff VK, Starrett JE Jr, and McIntosh TK (2001) The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J Cereb Blood Flow Metab 21:396-403.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1993-1996.
5. Dehal SS and Kupfer D (1999) Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 27:681-688.
6. 3H labeled (S)-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl) -2H-indol-2-one, Maxipost™, an agent for post-stroke neuroprotection. J Labelled Compd Radiopharm 46:139-149.
7. Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adduces: an industrial perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16.
8. Frantz SW, Srinivas N, Dominick M, Kelly W, Sanderson T, and Schilling B (2000) Safety assessment of BMS-204352, a novel therapeutic agent for the treatment of acute stroke. Eur J Neurol 7 (Suppl 3):110.
9. Gribkoff VK, Starrett Jr JE, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Herman K, Hibbard JR, Huston K, et al. (2001) Targeting acute ischemic stroke with a calcium sensitive opener of Maxi-K potassium channels. Nat Med 7:471-477.
10. Gibaldi M and Perrier D (1982) Pharmacokinetics, ed 2. Marcel Dekker, Inc., New York.
11. Krishna R, Palme H, Zeng J, and Srinivas NR (2002a) Effect of dose and input rate on the brain penetration of BMS-204352 following intravenous administration to rats. Biopharm Drug Dispos 23:227-231.
12. Krishna R, Palme H, Zeng J, and Srinivas NR (2002b) Pharmacokinetics and dose proportionality of BMS-204352 after intraarterial administration to rats. Biopharm Drug Dispos 23:233-237.
13. Krishna R, Shah V, Mantha S, Vachharajani N, and Srinivas NR (2002c) Pharmacokinetics and dose proportionality of BMS-204352 after intravenous administration to dogs. Biopharm Drug Dispos 23:83-86.
14. Krishna R, Yao M, Srinivas NR, Shah V, Pursley J, Arnold M, and Vachharajani N (2002d) Disposition of radiolabeled BMS-204352 in rats and dogs. Biopharm Drug Dispos 23:41-46.
15. Lai WG, Gardner I, Zahid N, and Uetrecht JP (2000) Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis. Drug Metab Dispos 28:255-263.
16. Monks TJ and Jones DC (2002) The metabolism and toxicity of quinones, quinonimines, quinone methide and quinone-thioether. Curr Drug Metab 3:425-438.
17. Morris MA and Preddy L (1986) Glycosylation accelerates albumin degradation in normal and diabetic dogs. Biochem Med Metab Biol 35:267-270.
18. Pumford NR and Halmes C (1997) Protein targets of xenobiotic reactive intermediates. Annu Rev Pharmacol Toxicol 37:91-117.
19. Reed RG, Davison LK, Burrington CM, and Peters T Jr (1988) Non-resolving jaundice: bilirubin covalently attached to serum albumin circulates with the same metabolic half-life as albumin. Clin Chem 34:1992-1994.
20. Schreiber G, Urban J, Zahringer J, Reutter VV, and Frosch U (1970) The secretion of serum protein and the synthesis of albumin and total protein in regenerating rat liver. J Biol Chem 246:4531-4538.
21. Sujatha N, Suryakala S, and Rao BS (2001) Enzyme immunoassay for aflatoxin B1-lysine adduct and its validation. J Assoc Off Anal Chem 84:1465-1474.
22. Szweda LI, Uchida K, Tsai L, and Stadtman ER (1993) Inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonneal. Selective modification of an active-site lysine. J Biol Chem 268:3342-3347.
23. Thompson JA, Carlson TJ, Sun Y, Dwyer-Nield LD, and Malkinson AM (2001) Studies using structural analogs and inbred strain differences to support a role for quinone methide metabolites of butylated hydroxytoluene (BHT) in mouse lung tumor promotion. Toxicology 160:197-205.
24. Uetrecht JP (1992) The role of leukocyte-generated metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 24:299-366.
25. Uetrecht JP (2003) Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 8:832-837.
26. Velayudham LS and Farrell GC (2003) Drug-induced cholestasis. Expert Opin Drug Safety 2:287-304.
27. Williams GR, Jiang JG, Atchar DB, and Samsa GP (1999) Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 30:2523-2528.
28. Yost GS (1989) Mechanisms of 3-methylindole pneumotoxicity. Chem Res Toxicol 2:273-279.
29. 14C]BMS-275291 in cryopreserved hepatocytes of mice, rabbits, dogs, monkeys and humans and correlation with in vivo biotransformation in BDC rats. Drug Metab Rev 32 (Suppl 2):260.
30. Zhang DL, Ogan M, Gedamke R, Roongta V, Dai R, Zhu M, Rinehart K, Klunk L, and Mitroka J (2003) Protein covalent binding of MaxiPost through a P450-mediated ortho-quinone methide intermediate in rats. Drug Metab Dispos 31:837-845.
31. Zhang DL, Zhao W, Roongta V, Mitroka J, Klunk L, and Zhu M (2004) Amide N-glucuronidation of MaxiPost catalyzed by UGT 2B7 in humans. Drug Metab Dispos 32:545-551.